Summary
A 2% commercial solution formulation of 5-fluorouracil (5-FU) was significantly better at delivering 5-FU than either a 1% or 5% solution. Among single component suspension formulations the highest transdermal delivery was obtained from the vehicle in which 5-FU was least soluble, isopropyl myristate (IPM), while changes in the total suspended concentration of 5-FU in propyleneglycol (PG) had no significant effect on transdermal delivery by those suspensions. A prodrug of 5-FU/IPM was significantly better at delivering 5-FU than any of the formulations. The trends in relative rates of delivery of 5-FU by the formulations and the prodrug were the same in skin of hairless mice and humans. The mouse skin was about ten times more permeable than the human skin. Second application studies to assess skin damage caused by the formulations also showed the same trend in skin of hairless mice and humans: all of the formulations caused some damage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cohen JL, Stoughton RB (1974) Penetration of 5-fluorouracil in excised skin. J Invest Dermatol 62:507–509
Dillaha CJ, Jansen GT, Honeycutt WM, Holt CA (1963) Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol 88:247–256
Dillaha CJ, Jansen GT, Honeycutt MW, Holt CA (1965) Further studies with topical 5-fluorouracil. Arch Dermatol 92:410–417
Flynn GL, Smith RW (1972) Membrane diffusion. III. Influence of solvent composition and permeant solubility in membrane transport. J Pharm Sci 61:61–66
Goette DK (1981) Topical chemotherapy with 5-fluorouracil. J Am Acad Dermatol 4:633–649
Hadgraft J, Walters KA, Wotton PK (1968) Facilitated percutaneous absorption: a comparison and evaluation of two in vitro models. Int J Pharm 32:257–263
Higuchi T (1960) Physical chemical analyses of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem 11:85–97
Kurihara-Bergstrom T, Flynn GL, Higuchi WI (1987) Physicochemical study of percutaneous absorption enhancement by dimethyl sulfoxide: dimethyl sulfoxide mediation of Vidarabine (ara-A) permeation of hairless mouse skin. J Invest Dermatol 89:274–280
Malzfeldt E, Lehman P, Goerz G, Lippold BC (1989) Influence of drug solubility in the vehicle on clinical efficacy of ointments. Arch Dermatol Res 281:193–197
Mollgaard B, Hoelgaard A (1983) Vehicle effect on topical drug delivery. II. Concurrent skin transport of drugs and vehicle components. Acta Pharm Suec 20:443–450
Robinson TA, Kligman AM (1975) Treatment of solar keratoses of the extremities with retinoic acid and 5-fluorouracil. Br J Dermatol 92:703–706
Sherertz EF, Sloan KB, McTiernan RG (1987) Use of theoretical partition coefficients determined from solubility parameters to predict permeability coefficients for 5-fluorouracil. J Invest Dermatol 89:147–151
Sherertz EF, Sloan KB, McTiernan RG (1987) Effect of skin pretreatment with vehicle alone or drug in vehicle on flux of a subsequently applied drug: results of hairless mouse skin and diffusion cell studies. J Invest Dermatol 89:249–252
Simmonds WL (1973) Double-blind investigation comparing a 1% vs 5% 5-fluorouracil topical cream in patients with multiple actinic keratoses. Cutis 12:615–617
Sloan KB, Koch SAM, Siver KG, Flower FP (1986) Use of solubility parameters of drug and vehicle to predict flux through skin. J Invest Dermatol 87:244–252
Sloan KB, Sherertz EF, McTiernan RG (1988) The effect of structure of Mannich base prodrugs on their ability to deliver theophylline and 5-fluorouracil through hairless mouse skin. Int J Pharm 44:87–96
Tonitou E, Abed L (1985) Effect of propylene glycol, Azone and n-decylmethyl sulphoxide on skin permeation kinetics of 5-fluorouracil. Int J Pharm 27:89–98
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sherertz, E.F., Sloan, K.B. & McTiernan, R.G. Transdermal delivery of 5-fluorouracil through skin of hairless mice and humans in vitro: a comparison of the effect of formulations and a prodrug. Arch Dermatol Res 282, 463–468 (1990). https://doi.org/10.1007/BF00402624
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00402624